{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-035613","form_type":"8-K","ticker":"NKTX","cik":"0001787400","company_name":"Nkarta, Inc.","filed_at":"2024-03-25T23:59:59+00:00","discovered_at":"2026-05-14T18:03:25.536070+00:00","generated_at":"2026-06-04T08:35:23.868364+00:00","sec_items":["8.01","7.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Nkarta shares NKX019 B-cell reconstitution and PK data from Phase 1 NHL trial","bullets":["After NKX019 treatment, circulating CD19+ cells rapidly depleted; B-cell repertoire recovered with naïve, non-class-switched isotypes in 5 patients at 3 months.","No patients had prior CAR T therapy; recovery pattern consistent with CAR T experience in autoimmune disease.","Preliminary PK data from 2 patients with DLBCL show similar NKX019 exposure after Flu/Cy vs Cy alone lymphodepletion.","B-cell recovery confirmed by single-cell RNA profiling, showing naïve and intermediate B cell transcriptome profiles.","Company highlights potential of NKX019 for autoimmune diseases such as lupus nephritis."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-035613","json":"https://secwatch.observer/filing/0000950170-24-035613.json","markdown":"https://secwatch.observer/filing/0000950170-24-035613.md","text":"https://secwatch.observer/filing/0000950170-24-035613.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1787400/000095017024035613/0000950170-24-035613-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1787400/000095017024035613/nktx-20240325.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-04T08:35:23.868364+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}